Vast Therapeutics

Executive Summary

Vast Therapeutics is a private, Phase 3-stage biotechnology company headquartered in Durham, NC, focused on developing breakthrough small molecule therapies for chronic respiratory diseases. Founded in 2017, the company aims to restore normal quality of life for patients suffering from conditions such as cystic fibrosis, COPD, or other debilitating respiratory disorders. While the company's specific pipeline details are not publicly disclosed, its advanced stage in clinical development suggests a lead asset is nearing regulatory milestones. Vast Therapeutics' mission emphasizes enabling patients to engage in everyday activities like shopping, walking, and spending time with family—highlighting the functional impact of their potential therapies. As a privately held firm with limited public information, Vast Therapeutics represents an early-stage opportunity in the respiratory disease space, with its Phase 3 status indicating significant progress toward potential commercialization.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Top-Line Data Readout65% success
• Q4 2026NDA Submission50% success
• Q2 2026Strategic Partnership or Licensing Deal40% success